Bioperfectus SARS-CoV-2 Antigen Rapid Test Kit with High Sensitivity and Specificity Assists in Fight against COVID-19 Pandemic
By HospiMedica International staff writers Posted on 12 Mar 2021 |
Image: Bioperfectus Novel Corona Virus (SARS-CoV-2) Antigen Rapid Test Kit (Photo courtesy of Jiangsu Bioperfectus Technologies Co., Ltd.)
Jiangsu Bioperfectus Technologies Co., Ltd.’s (Shanghai, China) Novel Corona Virus (SARS-CoV-2) Antigen Rapid Test Kit with clinically proven high sensitivity and specificity is playing an important role in COVID-19 diagnostics as a fast and cost-efficient antigen test.
While the reverse transcription real-time polymerase chain reaction (RT-PCR) assay, which is a nucleic acid amplification test (NAAT), remains the “gold standard” for COVID-19 diagnosis, rapid antigen tests, which detect the presence of viral proteins (antigens) are proving to be a faster and cheaper way for communities to detect ongoing infection. Despite their growing demand, there has been a shortage of COVID-19 rapid antigen tests in Europe due to the heavy reliance of EU countries on rapid antigen tests as a surplus testing option through the next phase of the pandemic, slow pace of vaccination, and a comparatively weak supply chain.
Bioperfectus Novel Corona Virus (SARS-CoV-2) Antigen Rapid Test Kit with its clinical proven accuracy is helping healthcare workers to quickly find out whether someone is currently at risk of spreading the disease, which will effectively curb the further spread of the virus. Bioperfectus COVID-19 rapid antigen test has been clinically proven to have high sensitivity of 96.7% and specificity of 97.9% by several institutes worldwide. Additionally, in a recent evaluation performed by the UK Department of Health and Social Care, Bioperfectus COVID-19 rapid antigen test showed no drop off in sensitivity when compared with the wild type with respect to the following variants - VOC1 Kent, UK, B.1.1.7 and VOC2 South Africa, B.1.351.
Bioperfectus Novel Corona Virus (SARS-CoV-2) Ag Rapid Test offers nasal, nasopharyngeal and oropharyngeal swab in both sterile tube and sterile peel-down pouch packages to meet the varied testing demands in different clinical laboratories across the world. Bioperfectus COVID-19 rapid antigen test also offers additional advantages such as fast results within 15 minutes, easy three-step use, swab with optional protective jacket to avoid biohazard, quality control for reliable results, and inclusion of all necessary components in the kit.
Related Links:
Jiangsu Bioperfectus Technologies Co., Ltd.
While the reverse transcription real-time polymerase chain reaction (RT-PCR) assay, which is a nucleic acid amplification test (NAAT), remains the “gold standard” for COVID-19 diagnosis, rapid antigen tests, which detect the presence of viral proteins (antigens) are proving to be a faster and cheaper way for communities to detect ongoing infection. Despite their growing demand, there has been a shortage of COVID-19 rapid antigen tests in Europe due to the heavy reliance of EU countries on rapid antigen tests as a surplus testing option through the next phase of the pandemic, slow pace of vaccination, and a comparatively weak supply chain.
Bioperfectus Novel Corona Virus (SARS-CoV-2) Antigen Rapid Test Kit with its clinical proven accuracy is helping healthcare workers to quickly find out whether someone is currently at risk of spreading the disease, which will effectively curb the further spread of the virus. Bioperfectus COVID-19 rapid antigen test has been clinically proven to have high sensitivity of 96.7% and specificity of 97.9% by several institutes worldwide. Additionally, in a recent evaluation performed by the UK Department of Health and Social Care, Bioperfectus COVID-19 rapid antigen test showed no drop off in sensitivity when compared with the wild type with respect to the following variants - VOC1 Kent, UK, B.1.1.7 and VOC2 South Africa, B.1.351.
Bioperfectus Novel Corona Virus (SARS-CoV-2) Ag Rapid Test offers nasal, nasopharyngeal and oropharyngeal swab in both sterile tube and sterile peel-down pouch packages to meet the varied testing demands in different clinical laboratories across the world. Bioperfectus COVID-19 rapid antigen test also offers additional advantages such as fast results within 15 minutes, easy three-step use, swab with optional protective jacket to avoid biohazard, quality control for reliable results, and inclusion of all necessary components in the kit.
Related Links:
Jiangsu Bioperfectus Technologies Co., Ltd.
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans